Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mentice ABFRA:MN2 -4.15%75 Net Margin % is -1.10% as of Jun. 2026. GuruFocus rates FRA:MN2 with a GF Score™ of 75/100 and a GF Value™ of €1.91 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Mentice AB ranks worse than 55.51% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Mentice AB's Net Income for the
three
months ended in Jun. 2026 was €-0.08 Mil. Mentice AB's Revenue for the
three
months ended in Jun. 2026 was €7.26 Mil. Therefore, Mentice AB's net margin for the quarter that ended in Jun. 2026 was -1.10%.
The historical rank and industry rank for Mentice AB's Net Margin % or its related term are showing as below:
FRA:MN2'
s Net Margin % Range Over the Past 10 Years
Min: -15.77 Med: -9.52 Max: 12.83
Current: -1.52
FRA:MN2's Net Margin % is ranked worse than 55.51% of 816
companies
in the Medical Devices & Instruments industry
Industry Median: 2.07
vs FRA:MN2: -1.52
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Mentice AB Net Margin % Related Terms
Mentice AB Net Margin % Historical Data
* Premium members only.
The historical data trend for Mentice AB's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Mentice AB's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mentice AB Net Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Mentice AB's Net Margin % distribution charts can be found below:
* The bar in red indicates where Mentice AB's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mentice AB (FRA:MN2) has a Net Margin % of -1.10% as of Jun. 2026. Net margin is the ratio of total net income to net sales. View historical data on Mentice AB and its competitors. According to the industry distribution chart, Mentice AB ranks #453 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 55.5%.
Is Mentice AB's Net Margin % too high?
Mentice AB's current Net Margin % is -1.10%. Based on the distribution chart, Mentice AB ranks #453 out of 816 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Mentice AB has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Mentice AB's Net Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Mentice AB ranks #453 out of 816 companies for Net Margin %. This places Mentice AB in the lower half of its industry. The industry median Net Margin % is 2.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Devices & Instruments company?
The median Net Margin % among Medical Devices & Instruments companies is 2.07, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Mentice AB and its competitors. For the Medical Devices & Instruments industry, the median Net Margin % is 2.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mentice AB's current Net Margin % is -1.10%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mentice AB stock overvalued right now?
Based on GuruFocus' analysis, Mentice AB (FRA:MN2) is currently considered Significantly Undervalued. The stock's GF Value™ is €1.91, compared to a current price of €1.27 — trading 33.5% below its estimated fair value. The current Net Margin % is -1.10%. Mentice AB's overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Mentice AB (FRA:MN2), the current Net Margin % is -1.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mentice AB (FRA:MN2) Overvalued in 2026?
Based on GuruFocus' analysis, Mentice AB stock appears to be undervalued.
The current stock price of €1.27 is trading 33.5% below its estimated GF Value™ of €1.91.
GuruFocus considers Mentice AB to be Significantly Undervalued.
Key valuation signals for FRA:MN2:
Net Margin %: -1.10%
GF Value™: €1.91 vs. price of €1.27 (33.5% below fair value)
No single metric tells the full story. See the FRA:MN2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mentice AB is a provider of software and hardware simulation solutions for image guided interventional therapies, offering proficiency based simulation solutions that help healthcare professionals acquire, retain, and enhance procedural skills, improving productivity and outcomes. Its solutions are scientifically validated and developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular, and peripheral interventions are covered. Mentice operates in two segments: Medical Device Industry (MDI), providing end-to-end solutions supporting development and launch of interventional therapies, and Healthcare Systems (HCS). Product areas include Mentice VIST, Physical Sim, Mentice Live, and Ankyras. It operates in EMEA, APAC, and the Americas.
75GF Score
Get the complete analysis for FRA:MN2
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:MN2 has been successfully added to your 
